Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_assertion type Assertion NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_head.
- NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_assertion description "[The mean log(10) HCV RNA differences for the best-performing CAP/CTM v2/MMx2 formulation in comparison to CAM were -0.05, 0.05, -0.12, -0.10, -0.44, and -0.29 for patients with GT1, GT2, GT3, GT4, GT5, and GT6 infections, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_provenance.
- NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_assertion evidence source_evidence_literature NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_provenance.
- NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_assertion SIO_000772 21752967 NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_provenance.
- NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_assertion wasDerivedFrom befree-20140225 NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_provenance.
- NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_assertion wasGeneratedBy ECO_0000203 NP464955.RA9Rzvqb_W5ghF3UUu3jzdCNYQ13bgVr2IK81rahQYAMo130_provenance.